AstraZeneca says its Oxford vaccine deal allows it to add up to 20% of manufacturing costs

"In addition to the manufacturing costs, the company is incurring costs in excess of $1 billion globally that include clinical development, regulatory, distribution, pharmacovigilance and other expenses", an AstraZeneca spokesman said in a statement.

from Moneycontrol Latest News https://ift.tt/3oq2qbQ